Citius Pharmaceuticals, Inc. develops innovative therapeutics for patients with critical diseases. The company focuses on advancing medical treatments for conditions such as infectious diseases and oncology. The company self-described as unlocking potential faster.

Citius Pharmaceuticals, Inc.

Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of critical care products focusing on anti-infective products in adjunct cancer care, prescription products, and mesenchymal stem cell therapy. The company is developing five proprietary products comprising Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome; and I/ONTAK, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 7, 2024 5:09 AM	febaf632
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 7, 2024 5:09 AM	ed27e714
crunchbase trigger	general	Nov 7, 2024 5:09 AM	8d7ed8da
crunchbase profile	general
li profile	general	Nov 7, 2024 5:09 AM	d38fc8aa
translate crunchbase fundingrounds	general
peers	general	Nov 7, 2024 5:09 AM	7ba7d3c4
news basic	general	Nov 7, 2024 5:09 AM	48fa9092
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:CITIUSPHARMA

Citius Pharmaceuticals, Inc.

Last Close

0.17

21/11 21:00

Market Cap

134.75M

Beta: -

Volume Today

4.54M

Avg: -